SCHEMBL4847487

SCHEMBL4847487

Cc1cc(-c2c(N3CCCC(C)C3)c3cc(Cl)ccc3[nH]c2=O)on1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 18/20 0.61
MAPT P10636 1/20 0.42
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4844211 0.89 CSF1R (0.62) CSF1R
SCHEMBL4848995 0.88 CSF1R (0.66) CSF1R
SCHEMBL4844116 0.88 CSF1R (0.66) CSF1R
SCHEMBL4849470 0.83 CSF1R (0.60) CSF1R
SCHEMBL4849642 0.83 CSF1R (0.60) CSF1RMAPT
SCHEMBL4851504 0.81 CSF1R (0.58) CSF1R
SCHEMBL4846029 0.81 CSF1R (0.58) CSF1R
SCHEMBL4844308 0.76 CSF1R (1.00) CSF1R
SCHEMBL4849368 0.76 CSF1R (1.00) CSF1R
SCHEMBL17457331 0.75 BRD4 (0.53) CSF1RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US claimed
EP-1660087-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP claimed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US claimed
WO-2005009967-A2 QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-03 WO claimed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
US-7326788-B2 Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-05 US disclosed
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049274-A1 Quinolinone derivatives as inhibitors of c-fms kinase FLT3, ABL1, FES CSF1R 192/4885MAPT 472/4885POLB 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.